Naomi Hillery
Overview
Explore the profile of Naomi Hillery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Syed R, Catanzaro D, Hillery N, Crudu V, Tudor E, Ciobanu N, et al.
PLoS One
. 2024 Dec;
19(12):e0313270.
PMID: 39636841
Objectives: This study aims to determine the progression rate, risk factors and timeline for the progression from exposure to active tuberculosis (TB) in a high-risk population. Using a prospective cohort...
2.
Seifert M, Catanzaro D, Gracia M, Hillery N, Tahseen S, Masood F, et al.
Clin Infect Dis
. 2024 Sep;
80(1):180-188.
PMID: 39233548
Background: An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed. Methods: A prospective evaluation of the Cepheid GeneXpert Mycobacterium tuberculosis Host Response cartridge (Xpert-MTB-HR), a prototype blood-based...
3.
Pan S, Catanzaro D, Seifert M, Syed R, Hillery N, Ho M, et al.
J Microbiol Immunol Infect
. 2023 Aug;
56(5):1073-1083.
PMID: 37580184
Objectives: To assess associations between disease severity in index TB patients and QuantiFERON-TB Gold Plus (QFT-Plus) results in contacts, and predictors for QFT-Plus conversion in contacts over 6-12 months. Methods:...
4.
Groessl E, Tally S, Hillery N
Clinicoecon Outcomes Res
. 2023 Apr;
15:239-250.
PMID: 37041933
Purpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory impairment, decreased quality of life, and high health care costs. Recent...
5.
Syed R, Catanzaro D, Colman R, Cooney C, Linger Y, Kukhtin A, et al.
J Clin Microbiol
. 2023 Feb;
61(3):e0147822.
PMID: 36757183
While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for...
6.
Hillery N, Seifert M, Catanzaro D, McKinnon S, Colman R, Chiles P, et al.
JMIR Res Protoc
. 2021 Jul;
10(7):e26748.
PMID: 34259165
Background: The lack of accurate and efficient diagnostic devices for extensively drug-resistant tuberculosis (XDR-TB) makes it a severe threat to global public health. A prospective clinical study in an intended-use...
7.
Catanzaro D, Colman R, Linger Y, Georghiou S, Kukhtin A, Seifert M, et al.
J Clin Microbiol
. 2020 Aug;
58(11).
PMID: 32817085
Despite the WHO's call for universal drug susceptibility testing for all patients being evaluated for tuberculosis (TB), a lack of rapid diagnostic tests which can fully describe TB resistance patterns...
8.
Groessl E, Tally S, Hillery N, Maciel A, Garces J
J Manag Care Spec Pharm
. 2018 Jul;
24(8):726-734.
PMID: 30058980
Background: Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process....
9.
Groessl E, Ganiats T, Hillery N, Trollip A, Jackson R, Catanzaro D, et al.
BMC Infect Dis
. 2018 Mar;
18(1):102.
PMID: 29499645
Background: Growth-based drug susceptibility testing (DST) is the reference standard for diagnosing drug-resistant tuberculosis (TB), but standard time to result (TTR) is typically ≥ 3 weeks. Rapid tests can reduce...
10.
Catanzaro A, Rodwell T, Catanzaro D, Garfein R, Jackson R, Seifert M, et al.
PLoS One
. 2015 Sep;
10(8):e0136861.
PMID: 26322781
Background: The aim of this study was to compare the performance of several recently developed assays for the detection of multi- and extensively drug-resistant tuberculosis (M/XDR-TB) in a large, multinational...